NASDAQ:ACIU AC Immune (ACIU) Stock Forecast, Price & News $2.85 -0.05 (-1.72%) (As of 04:31 PM ET) Add Compare Share Share Today's Range$2.84▼$2.9350-Day Range$2.77▼$3.3852-Week Range$1.68▼$3.83Volume28,947 shsAverage Volume413,933 shsMarket Capitalization$238.32 millionP/E RatioN/ADividend YieldN/APrice Target$16.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media AC Immune MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside461.4% Upside$16.00 Price TargetShort InterestHealthy1.09% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.25Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.71) to ($0.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.90 out of 5 starsMedical Sector729th out of 972 stocksPharmaceutical Preparations Industry345th out of 451 stocks 3.5 Analyst's Opinion Consensus RatingAC Immune has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.00, AC Immune has a forecasted upside of 461.4% from its current price of $2.85.Amount of Analyst CoverageAC Immune has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.09% of the float of AC Immune has been sold short.Short Interest Ratio / Days to CoverAC Immune has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AC Immune has recently increased by 17.27%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAC Immune does not currently pay a dividend.Dividend GrowthAC Immune does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACIU. Previous Next 2.4 News and Social Media Coverage News SentimentAC Immune has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for AC Immune this week, compared to 1 article on an average week.Search Interest3 people have searched for ACIU on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AC Immune insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of AC Immune is held by insiders.Percentage Held by InstitutionsOnly 19.17% of the stock of AC Immune is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AC Immune are expected to grow in the coming year, from ($0.71) to ($0.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AC Immune is -3.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AC Immune is -3.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAC Immune has a P/B Ratio of 1.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About AC Immune (NASDAQ:ACIU) StockAC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Read More ACIU Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACIU Stock News HeadlinesSeptember 29, 2023 | americanbankingnews.comHead-To-Head Comparison: PyroGenesis Canada (NASDAQ:PYR) and AC Immune (NASDAQ:ACIU)September 24, 2023 | americanbankingnews.comAC Immune (NASDAQ:ACIU) and Trevena (NASDAQ:TRVN) Critical AnalysisSeptember 29, 2023 | Stansberry Research (Ad)A 73-Year-Old Market Signal With 95% Accuracy Just FlashedThis signal has flashed just 24 times in the past 73 years – and it has signaled the exact moment to move your money with 95% accuracy. Now, it's flashing again. Discover where here.September 5, 2023 | finance.yahoo.comAre Options Traders Betting on a Big Move in AC Immune (ACIU) Stock?September 5, 2023 | finance.yahoo.comAC Immune (ACIU) Surges 43% in the Past 3 Months: Here's WhySeptember 5, 2023 | finance.yahoo.comAC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023August 7, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on AC Immune SA (ACIU)August 4, 2023 | finance.yahoo.comAC Immune (ACIU) Reports Q2 Loss, Misses Revenue EstimatesSeptember 29, 2023 | Altimetry (Ad)Surprising "Twist" Hands Biden Landslide Re-election?This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.August 4, 2023 | finance.yahoo.comAC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate UpdateJuly 28, 2023 | finanznachrichten.deAC Immune SA: AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023July 28, 2023 | finance.yahoo.comAC Immune to Present at the BTIG Virtual Biotechnology Conference 2023July 26, 2023 | finance.yahoo.comAC Immune SA Appoints New Chief Medical OfficerJuly 3, 2023 | finance.yahoo.comAC Immune Showcasing Precision Medicine Programs at AAIC 2023July 2, 2023 | fool.comAc Immune (NASDAQ: ACIU)June 30, 2023 | finance.yahoo.comWhy Shares of AC Immune Jumped This WeekJune 28, 2023 | markets.businessinsider.comAC Immune SA (ACIU) Gets a Buy from H.C. WainwrightJune 27, 2023 | msn.comWhy AC Immune Stock Skyrocketed TodayJune 27, 2023 | theglobeandmail.comBiotech Pops On FDA Fast Track DesignationJune 27, 2023 | finanznachrichten.deAC Immune SA: AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer's DiseaseJune 27, 2023 | msn.comAC Immune’s stock soars 13% after FDA grants fast-track designation to Alzheimer’s treatmentJune 27, 2023 | msn.comAC Immune gains 14% on FDA fast track tag for Alzheimer’s vaccineJune 27, 2023 | finance.yahoo.comAC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s DiseaseJune 16, 2023 | finance.yahoo.comPrivate equity firms among AC Immune SA's (NASDAQ:ACIU) largest stockholders and were hit after last week's 12% price dropJune 12, 2023 | finance.yahoo.comACIU - AC Immune SAMay 1, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for AC Immune SA (ACIU)April 28, 2023 | finanznachrichten.deAC Immune SA: AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate UpdateSee More Headlines Receive ACIU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter. Email Address ACIU Company Calendar Last Earnings8/04/2023Today9/29/2023Next Earnings (Estimated)10/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACIU CUSIPN/A CIK1651625 Webwww.acimmune.com Phone(121) 345-9121Fax41-21-345-9120Employees126Year FoundedN/APrice Target and Rating Average Stock Price Forecast$16.00 High Stock Price Forecast$16.00 Low Stock Price Forecast$16.00 Forecasted Upside/Downside+451.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,140,000.00 Net MarginsN/A Pretax Margin-1,743.45% Return on Equity-40.98% Return on Assets-37.22% Debt Debt-to-Equity RatioN/A Current Ratio8.89 Quick Ratio8.89 Sales & Book Value Annual Sales$4.12 million Price / Sales58.86 Cash FlowN/A Price / Cash FlowN/A Book Value$2.12 per share Price / Book1.37Miscellaneous Outstanding Shares83,620,000Free Float79,773,000Market Cap$242.50 million OptionableNot Optionable Beta0.67 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Andrea Pfeifer Ph.D. (Age 66)Co-Founder, CEO & Director Comp: $1.11MMr. Christopher Roberts (Age 34)Interim CFO & VP of Fin. Mr. Piergiorgio Donati (Age 52)Chief Technical Operations Officer Dr. Marie Kosco-Vilbois (Age 65)Chief Scientific Officer Mr. Jean-Fabien Monin (Age 52)Chief Admin. Officer Mr. Howard Donovan (Age 48)Chief HR Officer Prof. Johannes Rolf Streffer M.D. (Age 54)Chief Medical Officer Mr. Joshua Drumm Ph.D.Head of Investor RelationsMr. Alexandre Caratsch (Age 57)Gen. Counsel Judith MooreGlobal Head of CommunicationsMore ExecutivesKey CompetitorsXeris BiopharmaNASDAQ:XERSAtea PharmaceuticalsNASDAQ:AVIRscPharmaceuticalsNASDAQ:SCPHVanda PharmaceuticalsNASDAQ:VNDAReneo PharmaceuticalsNASDAQ:RPHMView All CompetitorsInstitutional OwnershipWells Fargo & Company MNBought 162,926 shares on 8/15/2023Ownership: 1.363%Citadel Advisors LLCBought 1,400 shares on 8/15/2023Ownership: 0.000%Platinum Investment Management Ltd.Bought 240,000 shares on 8/11/2023Ownership: 1.582%Renaissance Technologies LLCBought 6,900 shares on 8/11/2023Ownership: 0.500%Banque Cantonale VaudoiseBought 14,898 shares on 8/9/2023Ownership: 0.097%View All Institutional Transactions ACIU Stock - Frequently Asked Questions Should I buy or sell AC Immune stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACIU shares. View ACIU analyst ratings or view top-rated stocks. What is AC Immune's stock price forecast for 2023? 1 brokerages have issued 12 month target prices for AC Immune's shares. Their ACIU share price forecasts range from $16.00 to $16.00. On average, they expect the company's share price to reach $16.00 in the next year. This suggests a possible upside of 451.7% from the stock's current price. View analysts price targets for ACIU or view top-rated stocks among Wall Street analysts. How have ACIU shares performed in 2023? AC Immune's stock was trading at $2.04 at the beginning of 2023. Since then, ACIU stock has increased by 42.2% and is now trading at $2.90. View the best growth stocks for 2023 here. Are investors shorting AC Immune? AC Immune saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 455,000 shares, an increase of 17.3% from the August 31st total of 388,000 shares. Based on an average trading volume of 971,900 shares, the days-to-cover ratio is presently 0.5 days. Currently, 1.1% of the shares of the stock are short sold. View AC Immune's Short Interest. When is AC Immune's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, October 27th 2023. View our ACIU earnings forecast. How were AC Immune's earnings last quarter? AC Immune SA (NASDAQ:ACIU) released its quarterly earnings data on Friday, August, 4th. The company reported ($0.22) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.22). What is Andrea Pfeifer's approval rating as AC Immune's CEO? 3 employees have rated AC Immune Chief Executive Officer Andrea Pfeifer on Glassdoor.com. Andrea Pfeifer has an approval rating of 35% among the company's employees. This puts Andrea Pfeifer in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of AC Immune own? Based on aggregate information from My MarketBeat watchlists, some companies that other AC Immune investors own include Sorrento Therapeutics (SRNE), Agenus (AGEN), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Abeona Therapeutics (ABEO), AVEO Pharmaceuticals (AVEO), Catalyst Pharmaceuticals (CPRX), Ocular Therapeutix (OCUL), Rigel Pharmaceuticals (RIGL) and AbbVie (ABBV). When did AC Immune IPO? (ACIU) raised $55 million in an initial public offering (IPO) on Friday, September 23rd 2016. The company issued 4,600,000 shares at $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO. What is AC Immune's stock symbol? AC Immune trades on the NASDAQ under the ticker symbol "ACIU." How do I buy shares of AC Immune? Shares of ACIU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is AC Immune's stock price today? One share of ACIU stock can currently be purchased for approximately $2.90. How much money does AC Immune make? AC Immune (NASDAQ:ACIU) has a market capitalization of $242.50 million and generates $4.12 million in revenue each year. The company earns $-74,140,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. How many employees does AC Immune have? The company employs 126 workers across the globe. How can I contact AC Immune? AC Immune's mailing address is EPFL Innovation Park Building B, Lausanne V8, 1015. The official website for the company is www.acimmune.com. The company can be reached via phone at (121) 345-9121, via email at ir@acimmune.com, or via fax at 41-21-345-9120. This page (NASDAQ:ACIU) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AC Immune SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.